%0 Journal Article
%T Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
%A S Galimberti
%A M Petrini
%J Cancer Management and Research
%D 2010
%I 
%X S Galimberti, M PetriniDepartment of Oncology, Transplant and Advances in Medicine, Section of Hematology, University of Pisa, Pisa, ItalyAbstract: Patients with mantle cell lymphoma (MCL) have a poor prognosis; consequently, new therapeutic approaches, such as rapamycin and its derivates, mammalian target of rapamycin (mTOR) inhibitors, are warranted. Temsirolimus (also known as CCI-779), a dihydroester of rapamycin, in MCL cell lines inhibited mTOR, downregulated p21 and v-Raf, and induced autophagy.The first clinical trial in MCL patients was performed using 250 mg of temsirolimus weekly for 6¨C12 cycles. The overall response rate was 38%; the median time to progression was 6.5 months, median overall survival was 12 months, and the median duration of response was 6.9 months. At lower dose (25 mg/week), the overall response rate was 41%, median overall survival was 14 months, and time to progression was 6 months. In another trial, 162 patients were randomly assigned to receive temsirolimus at 2 different doses (175 mg/week for 3 weeks, then 75 mg or 25 mg/week) or a treatment chosen by the investigator among the most frequently adopted single agents for treatment of relapsed MCL. Patients treated with 175/75 mg of temsirolimus had significantly higher response rates and longer progression-free survival than those treated with investigatorĄ¯s choice therapy. These data support the use of mTOR inhibitors for the treatment of MCL, probably in combination with other agents, such as antiangiogenic drugs or histone acetylase inhibitors.Keyword: mTOR rapamycin, PI3K/Akt, p7056K, 4E-BP1
%U http://www.dovepress.com/temsirolimus-in-the-treatment-of-relapsed-andor-refractory-mantle-cell-a4667